For healthcare professionals
This section is written for the treating clinician and for the people who have to source the product: the oncologist whose patient cannot obtain a medicine that is not licensed locally, and the hospital pharmacy or procurement officer who has to bring it in lawfully.
It explains the regulatory routes that exist, what documentation each one requires, how supply is executed under Good Distribution Practice, and what evidence is provided with the consignment. It contains no pricing and no product claims.
Professional information
This section is written for prescribers, pharmacists and procurement staff. It is factual information provided in response to specific enquiries. It is not an advertisement for any medicine and contains no pricing and no product claims.
Who this section is for
Oncologists and prescribing physicians
Where a medicine is not registered in the country of treatment, the prescriber remains the person clinically responsible for the patient. This section sets out the named-patient route and the documentation the prescriber is asked to provide.
Hospital and specialty pharmacies
Batch traceability, cold-chain evidence, Certificate of Analysis and delivery documentation — what is supplied with each consignment and in what format.
Oncology centres and day units
Continuity of supply for named patients across a course of treatment, and the documentation required for repeat consignments.
Procurement departments
Supplier due diligence, İTS serial-level notification records, GDP cold-chain controls, suspect-product handling and the written quotation process.
Licensed distributors and wholesalers
Business-to-business supply against a confirmed specification, within the import permissions of the destination country.
What this section covers
- Named patient supply
- The internationally recognised route by which a physician obtains a medicine not licensed in their country for a specific identified patient — the conditions, the notification requirements and the limits.
- Sourcing process
- The step-by-step operational workflow from enquiry to delivery documentation, and the point at which each document is required.
- Quality and compliance
- Türkiye İTS track-and-trace, EU GDP cold-chain requirements, Certificate of Analysis format and the suspect-product procedure.
- Request a quotation
- A structured enquiry form for clinicians and procurement, separate from the patient enquiry channel.
Two rules that apply without exception
- No supply proceeds without a valid prescription issued by the physician responsible for the patient.
- Where the destination country requires an import permit, no supply proceeds until that permit is in place.
Country import routes
Destination-specific requirements, with the national authority named in each case.
Legal and licensing identity
Registry, licence and responsible-pharmacist details are published here once the corresponding documents are verified. Nothing is shown until then.
Request a quotation
Structured enquiry for prescribers, hospital pharmacies and procurement departments. Specify INN, brand, strength, presentation, quantity and required delivery window.
Frequently asked questions
Do you supply hospitals and clinics directly?
Yes. Supply to hospitals, oncology centres, specialty pharmacies and licensed distributors is business-to-business, against a confirmed written specification and within the import permissions of the destination country.
Do you publish prices?
No. Unlicensed medicines and specials must not be advertised. A written quotation is issued in response to a specific enquiry, against a confirmed specification.
What do you need from the prescriber?
The INN, brand, strength, presentation, quantity and required delivery window; a valid prescription; and, where the destination authority requires them, a medical report or physicians' council protocol and an import permit.
Which languages is this section available in?
English and Arabic for all pages; Russian and Azerbaijani for the section hub, named patient supply, and quality and compliance.
Last reviewed: 2026-07-29